Oramed recruits patients for Type 1 diabetes oral insulin trial

Israeli oral drug delivery developer Oramed has begun recruiting patients for a clinical trial of its oral insulin pill for patients with Type 1 diabetes mellitus. The pill, ORMD-0801, is set to undergo a Phase IIa trial for Type 2 diabetes, as well, getting closer to becoming the first orally digestible insulin capsule on the market. Meanwhile, other companies such as Novo Nordisk ($NVO), Bristol-Myers Squibb ($BMY) and India's Biocon are champing at the bit to launch insulin pills of their own. Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…